Genomic analysis in previous literature has revealed that up to 40% of DLBCL, LT cases have recurrent genetic alterations in PD-L1/PD-L2, presenting a hopeful future possibility for PD-1 checkpoint inhibitors in this rare population.10 This evidence concerns the gene PDCD1LG2 and diffuse large B-cell lymphoma.